136 related articles for article (PubMed ID: 7226569)
1. Effect of dopamine infusion on serum prolactin concentration in normal and hyperprolactinaemic subjects.
Reschini E; Ferrari C; Peracchi M; Fadini R; Meschia M; Crosignani PG
Clin Endocrinol (Oxf); 1980 Dec; 13(6):519-23. PubMed ID: 7226569
[TBL] [Abstract][Full Text] [Related]
2. The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
Scanlon MF; Peters JR; Salvador J; Richards SH; John R; Howell S; Williams ED; Thomas JP; Hall R
Clin Endocrinol (Oxf); 1986 Apr; 24(4):435-46. PubMed ID: 3091297
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-dose dopamine infusion on anterior pituitary hormone secretion in normal female subjects.
Connell JM; Ball SG; Inglis GC; Beastall GH; Davies DL
Clin Sci (Lond); 1984 Aug; 67(2):219-23. PubMed ID: 6744790
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prolactin secretion by low-dose dopamine infusion in patients with hyperprolactinaemia.
Connell JM; Padfield PL; Bunting EA; Ball SG; Inglis GC; Beastall GH; Teasdale GM; Davies DL
Clin Endocrinol (Oxf); 1983 May; 18(5):527-32. PubMed ID: 6872271
[TBL] [Abstract][Full Text] [Related]
5. Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas.
Tallo D; Malarkey WB
Am J Obstet Gynecol; 1985 Mar; 151(5):651-5. PubMed ID: 3976764
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four hour secretory pattern of prolactin in hyperprolactinaemic patients with pituitary micro- and macroadenomas.
Seki K; Uesato T; Kato K; Shima K
Acta Endocrinol (Copenh); 1984 Aug; 106(4):433-6. PubMed ID: 6475455
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of two inhibitory tests (nomifensine and L-dopa + carbidopa) for the diagnosis of hyperprolactinaemic states.
Moriondo P; Travaglini P; Nissim M; Faglia G
Clin Endocrinol (Oxf); 1980 Dec; 13(6):525-33. PubMed ID: 7226570
[TBL] [Abstract][Full Text] [Related]
8. Prolactin-secreting pituitary adenomas: prolactin dynamics before and after transsphenoidal surgery.
Barbarino A; de Marinis L; Menini E; Anile C; Maira G
Acta Endocrinol (Copenh); 1979 Jul; 91(3):397-409. PubMed ID: 112818
[TBL] [Abstract][Full Text] [Related]
9. Prolactin secretion by mixed ACTH-prolactin pituitary adenoma cells in culture.
Yamaji T; Ishibashi M; Teramoto A; Fukushima T
Acta Endocrinol (Copenh); 1985 Apr; 108(4):456-63. PubMed ID: 2859725
[TBL] [Abstract][Full Text] [Related]
10. [Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)].
Bercovici JP; Khoury S; Tater D; Besson G; Caroff J
Biomed Pharmacother; 1983; 37(5):222-7. PubMed ID: 6661508
[TBL] [Abstract][Full Text] [Related]
11. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic inhibition of growth hormone and prolactin release during continuous in vitro perifusion of normal and adenomatous human pituitary.
Lawton NF; Evans AJ; Weller RO
J Neurol Sci; 1981 Feb; 49(2):229-39. PubMed ID: 7217982
[TBL] [Abstract][Full Text] [Related]
13. Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement.
Bevan JS; Burke CW; Esiri MM; Adams CB
Am J Med; 1987 Jan; 82(1):29-32. PubMed ID: 3799691
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal pattern of the TSH and PRL responses to dopamine receptor blockade in women with physiological or pathological hyperprolactinaemia.
Massara F; Camanni F; Martra M; Dolfin GC; Müller EE; Molinatti GM
Clin Endocrinol (Oxf); 1983 Feb; 18(2):103-10. PubMed ID: 6851194
[TBL] [Abstract][Full Text] [Related]
15. Metabolic clearance and production rates of prolactin in man.
Cooper DS; Ridgway EC; Kliman B; Kjellberg RN; Maloof F
J Clin Invest; 1979 Dec; 64(6):1669-80. PubMed ID: 583048
[TBL] [Abstract][Full Text] [Related]
16. Male prolactin secreting pituitary adenomas in humans studied by peroxidase-labelled antibody method.
Osamura RY; Watanabe K; Teramoto A; Hirakawa K; Kawano N; Morii S
Acta Endocrinol (Copenh); 1978 Aug; 88(4):643-52. PubMed ID: 356501
[TBL] [Abstract][Full Text] [Related]
17. Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas.
De Camilli P; Macconi D; Spada A
Nature; 1979 Mar; 278(5701):252-4. PubMed ID: 423973
[No Abstract] [Full Text] [Related]
18. A defect in catecholamine neurons in patients with prolactin-secreting pituitary adenoma.
Van Loon GR
Lancet; 1978 Oct; 2(8095):868-71. PubMed ID: 81414
[TBL] [Abstract][Full Text] [Related]
19. Lack of plasma prolactin response to intravenously injected vasoactive intestinal polypeptide in patients with prolactin-secreting adenoma.
Kaji H; Chihara K; Kita T; Kashio Y; Okimura Y; Fujita T
Acta Endocrinol (Copenh); 1985 Dec; 110(4):445-50. PubMed ID: 4090907
[TBL] [Abstract][Full Text] [Related]
20. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
Vance ML; Lipper M; Klibanski A; Biller BM; Samaan NA; Molitch ME
Ann Intern Med; 1990 May; 112(9):668-73. PubMed ID: 1970714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
